Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents

October 1, 2018

A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.

Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says

All Content © 2018, Portfolio Media, Inc.

Jake M. Holdreith


Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Related Publications

March 2023
Unintended Consequences of Banning Noncompete Agreements
Michael Geibelson, Stephen Safranski, Michael Pacelli - Bloomberg Law
March 26, 2023
December 8, 2022
Lessons From MMAS Research About Dispositive Pitfalls in Copyright Litigation
David Martinez, Austin Miller - Los Angeles & San Francisco Daily Journal
November 19, 2022
How to Use the USPTO Patent Public Search Tool
Miles Finn, Rajin Olson, Kelson Bain, and Ian LaForge - IPWatchdog
October 2022
In No Uncertain Terms
Bryan Mechell - The Robins Kaplan Quarterly
Back to Top